Your browser doesn't support javascript.
loading
Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN.
Dieudonné, Yannick; Gies, Vincent; Guffroy, Aurélien; Keime, Céline; Bird, Anna K; Liesveld, Jane; Barnas, Jennifer L; Poindron, Vincent; Douiri, Nawal; Soulas-Sprauel, Pauline; Martin, Thierry; Meffre, Eric; Anolik, Jennifer H; Korganow, Anne-Sophie.
  • Dieudonné Y; CNRS UPR 3572 "Immunopathology and Therapeutic Chemistry"/Laboratory of Excellence Medalis, Institute of Molecular and Cellular Biology (IBMC), Strasbourg, France; Department of Clinical Immunology and Internal Medicine, National Reference Center for Autoimmune Diseases, Hôpitaux Universitaires de S
  • Gies V; Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR - S1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France; Service d'Immunologie Biologique, Pôle de Biologie, Hôpitaux
  • Guffroy A; CNRS UPR 3572 "Immunopathology and Therapeutic Chemistry"/Laboratory of Excellence Medalis, Institute of Molecular and Cellular Biology (IBMC), Strasbourg, France; Department of Clinical Immunology and Internal Medicine, National Reference Center for Autoimmune Diseases, Hôpitaux Universitaires de S
  • Keime C; IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), INSERM, U1258, CNRS, UMR7104, Université de Strasbourg, Illkirch, France.
  • Bird AK; Department of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
  • Liesveld J; Blood and Marrow Stem Cell Transplant Program, Department of Internal Medicine and The James P. Wilmot Cancer Center, University of Rochester, New York 14642, USA.
  • Barnas JL; Department of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
  • Poindron V; CNRS UPR 3572 "Immunopathology and Therapeutic Chemistry"/Laboratory of Excellence Medalis, Institute of Molecular and Cellular Biology (IBMC), Strasbourg, France; Department of Clinical Immunology and Internal Medicine, National Reference Center for Autoimmune Diseases, Hôpitaux Universitaires de S
  • Douiri N; Department of Infectious Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Soulas-Sprauel P; CNRS UPR 3572 "Immunopathology and Therapeutic Chemistry"/Laboratory of Excellence Medalis, Institute of Molecular and Cellular Biology (IBMC), Strasbourg, France; Department of Clinical Immunology and Internal Medicine, National Reference Center for Autoimmune Diseases, Hôpitaux Universitaires de S
  • Martin T; CNRS UPR 3572 "Immunopathology and Therapeutic Chemistry"/Laboratory of Excellence Medalis, Institute of Molecular and Cellular Biology (IBMC), Strasbourg, France; Department of Clinical Immunology and Internal Medicine, National Reference Center for Autoimmune Diseases, Hôpitaux Universitaires de S
  • Meffre E; Departement of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
  • Anolik JH; Department of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
  • Korganow AS; CNRS UPR 3572 "Immunopathology and Therapeutic Chemistry"/Laboratory of Excellence Medalis, Institute of Molecular and Cellular Biology (IBMC), Strasbourg, France; Department of Clinical Immunology and Internal Medicine, National Reference Center for Autoimmune Diseases, Hôpitaux Universitaires de S
J Autoimmun ; 102: 150-158, 2019 08.
Article en En | MEDLINE | ID: mdl-31085070
ABSTRACT
Systemic lupus (SLE) is characterized by a break of B cell tolerance that plays a central role in disease pathophysiology. An early checkpoint defect occurs at the transitional stage leading to the survival of autoreactive B cells and consequently the production of pathogenic autoantibodies. The main purpose of our work was to determine whether transitional B cells, as the most immature naïve B cell subset upstream of pathogenic B cells, display specific features compared to healthy non SLE subjects. Through extensive analysis of transitional B cells from untreated or low treated, mostly Caucasian, SLE patients, we demonstrated that transitional (T1 and T2) B cell frequencies were increased in SLE and positively correlated with disease activity. SLE transitional B cells displayed defects in two closely inter-related molecules (i.e. TLR9 defective responses and CD19 downregulation). RNA sequencing of sorted transitional B cells from untreated patients revealed a predominant overexpression of interferon stimulated genes (ISGs) even out of flares. In addition, early transitional B cells from the bone marrow displayed the highest interferon score, reflecting a B cell interferon burden of central origin. Hence, the IFN signature in transitional B cells is not confined to African American SLE patients and exists in quiescent disease since the medullary stage. These results suggest that in SLE these 3 factors (i.e. IFN imprintment, CD19 downregulation and TLR9 responses impairment) could take part at the early transitional B cell stage in B cell tolerance by-pass, ultimately leading in periphery to the expansion of autoantibodies-secreting cells.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Interferones / Antígenos CD19 / Receptor Toll-Like 9 / Células Precursoras de Linfocitos B / Lupus Eritematoso Sistémico Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Interferones / Antígenos CD19 / Receptor Toll-Like 9 / Células Precursoras de Linfocitos B / Lupus Eritematoso Sistémico Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Año: 2019 Tipo del documento: Article